StreetInsider.com News Articles

Form SCHEDULE 13D/A Bluejay Diagnostics, Filed by: NORTHSTRIVE FUND II LP

Tue, 02 Jun 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260602/26594064.html

Form SCHEDULE 13D/A Bluejay Diagnostics, Filed by: NORTHSTRIVE FUND II LP

Tue, 02 Jun 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260602/26594064.html

Form SCHEDULE 13D/A Bluejay Diagnostics, Filed by: Braeden Lichti

Tue, 02 Jun 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260602/26593963.html

Form SCHEDULE 13D/A Bluejay Diagnostics, Filed by: Braeden Lichti

Tue, 02 Jun 2026 20:11:00 -0400

si-local-file:///var/storage/secattach/20260602/26593963.html

Bluejay Diagnostics raises $8.5 million in private placement

Tue, 02 Jun 2026 12:19:16 -0400

Bluejay Diagnostics Inc. (NASDAQ: BJDX) announced it has entered into definitive agreements for a private placement expected to generate $8.5 million in gross proceeds, with potential additional proceeds of up to $15.1 million if warrants are fully exercised.

The medical diagnostics company will sell 3,655,917 shares of common stock and accompanying warrants at $2.325 per share. The offering includes series G warrants and short-term series H warrants, both with an exercise price of $2.075 per share and immediate exercisability upon issuance.

The series G warrants will expire five years from the effective date of the resale registration statement, while the short-term series

Bluejay Diagnostics raises $8.5 million in private placement

Tue, 02 Jun 2026 12:19:16 -0400

The series G warrants will expire five years from the effective date of the resale registration statement, while the short-term series

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 02 Jun 2026 12:19:00 -0400

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond FDA approval and first full year of commercialization

ACTON, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on near-patient testing for critical care, today

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 02 Jun 2026 12:19:00 -0400

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 02 Jun 2026 12:19:00 -0400

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Tue, 02 Jun 2026 12:19:00 -0400

$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants

Form 8-K Bluejay Diagnostics, For: May 27

Tue, 02 Jun 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26586984.html

Form 8-K Bluejay Diagnostics, For: May 27

Tue, 02 Jun 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260602/26586984.html

Bluejay Diagnostics partners with Argonaut for US manufacturing

Tue, 02 Jun 2026 06:30:15 -0400

Bluejay Diagnostics Inc. (NASDAQ: BJDX) announced a strategic partnership with Argonaut Manufacturing Services to support the advancement of its Symphony platform for near-patient testing in critical care settings.

The collaboration aims to establish scalable U.S.-based manufacturing capabilities for Bluejay's diagnostic platform. The partnership is intended to support the company's clinical development programs and future commercialization objectives while reducing reliance on overseas manufacturing.

The agreement focuses on strengthening Bluejay's commercial infrastructure by supporting product distribution across the United States, enhancing supply chain resilience, and reducing risks associated with international sourcing and import tariffs. The domestic manufacturing capabilities are designed to provide greater operational

Bluejay Diagnostics partners with Argonaut for US manufacturing

Tue, 02 Jun 2026 06:30:15 -0400

Bluejay Diagnostics partners with Argonaut for US manufacturing

Tue, 02 Jun 2026 06:30:15 -0400

Bluejay Diagnostics partners with Argonaut for US manufacturing

Tue, 02 Jun 2026 06:30:15 -0400

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership